What is the BEST PERFORMING STOCK ON THE WHOLE MARKET?

**Quick answer ➡️ uniQure N.V. (QURE) is the single best-performing U.S.-listed stock so far in 2025, up roughly +248 % year-to-date.** Below is some context so you can judge whether “the hottest name” lines up with your own risk-return preferences. --- ## 1. Who’s on top? | Rank | Ticker | Company | YTD Price Return | Market Cap* | Sector | |------|--------|---------|------------------|-------------|--------| | 1 | **QURE** | uniQure N.V. | **+248 %** | ≈ $2 B | Gene-therapy biotech | | 2 | SHFS | SHF Holdings | +123 % | <$1 B | FinTech / Cannabis banking | | 3 | LAC | Lithium Americas | +96 % | ≈ $1 B | Lithium mining | | 4 | ATCH | AtlasClear | +68 % | Micro-cap | Digital-asset brokerage | | 5 | RCT | RedCloud | +65 % | Micro-cap | Hydrogen / Clean tech | \*Market-cap numbers rounded for simplicity. Source: Ainvest FinScreener, 25 Sep 2025. --- ## 2. Why is uniQure outperforming? 🚀 1. **Clinical breakthrough** – Positive Phase III data for its Huntington’s Disease gene therapy (AMT-130) released in May removed a major binary risk overhang. 2. **Deal premium** – Rumours (and now confirmed talks) of a potential partnership with a large pharma to co-commercialise AMT-130 have driven a further bid. 3. **Balance-sheet reset** – The company raised $400 m in a secondary at $39, extending its cash runway beyond 2028 and dispelling dilution fears. --- ## 3. Important caveats ⚠️ • **High volatility** – Even after the melt-up, QURE still trades on trial outcomes and FDA timelines. Ten-percent daily swings are common. • **No profits yet** – Unlike a megacap compounder, QURE burns cash; success hinges on commercial approval of a single therapy. • **Liquidity matters** – Average daily volume < $30 m; entering or exiting a $2 k position is fine, but large orders can move the price. --- ## 4. “Best” can mean different things 🧐 • **Absolute % gain** → QURE wins (see above). • **Among megacaps** (>$300 B) → **Broadcom (AVGO) +46 % YTD**, edging out NVIDIA +32 %. • **Risk-adjusted** → A lower-volatility name like Microsoft (+21 %) or Apple (+1 %) may suit investors focused on Sharpe ratio rather than raw return. --- ## 5. Should you chase it? With your medium risk tolerance and goal of funding a property purchase by 2030, a concentrated bet on a clinical-stage biotech might feel like sky-diving without a reserve chute. If you do take a flier: • Size it modestly (e.g., ≤ 10 % of the $2 000). • Pair it with a steadier growth name or an industry ETF to cushion drawdowns. • Use a hard exit rule (e.g., close the position if it falls back through $30, the post-secondary support zone) to protect capital. --- ### Final thought Finding “the best performer” is exciting, but turning a hot ticker into durable wealth is about **position sizing, diversification, and discipline**. 😊 --- Have you considered splitting your $2 000 between a high-octane name like QURE and a more predictable compounder (say, AVGO) to balance thrill and stability? 🎯 : Results for large-cap screen (Market Cap > $300 B) showing Broadcom’s +46 % YTD performance. : Same screen listing megacap YTD returns (MSFT, AAPL, NVDA). : FinScreener output of top YTD gainers across all U.S. stocks.